These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 20566858)

  • 1. Mycobacterium tuberculosis persistence mutants identified by screening in isoniazid-treated mice.
    Dhar N; McKinney JD
    Proc Natl Acad Sci U S A; 2010 Jul; 107(27):12275-80. PubMed ID: 20566858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of interactions of clinical mutants of catalase-peroxidase (KatG) responsible for isoniazid resistance in Mycobacterium tuberculosis with derivatives of isoniazid.
    Unissa AN; Doss C GP; Kumar T; Swathi S; Lakshmi AR; Hanna LE
    J Glob Antimicrob Resist; 2017 Dec; 11():57-67. PubMed ID: 28743650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of Novel Mycobacterium tuberculosis Isoniazid Resistance Mutations Not Detectable by Common Molecular Tests.
    Kandler JL; Mercante AD; Dalton TL; Ezewudo MN; Cowan LS; Burns SP; Metchock B; ; Cegielski P; Posey JE
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30082293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of enzymatic activities of new KatG mutants from low- and high-level isoniazid-resistant clinical isolates of Mycobacterium tuberculosis.
    Brossier F; Boudinet M; Jarlier V; Petrella S; Sougakoff W
    Tuberculosis (Edinb); 2016 Sep; 100():15-24. PubMed ID: 27553406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates.
    Torres JN; Paul LV; Rodwell TC; Victor TC; Amallraja AM; Elghraoui A; Goodmanson AP; Ramirez-Busby SM; Chawla A; Zadorozhny V; Streicher EM; Sirgel FA; Catanzaro D; Rodrigues C; Gler MT; Crudu V; Catanzaro A; Valafar F
    Emerg Microbes Infect; 2015 Jul; 4(7):e42. PubMed ID: 26251830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA.
    Guo H; Seet Q; Denkin S; Parsons L; Zhang Y
    J Med Microbiol; 2006 Nov; 55(Pt 11):1527-1531. PubMed ID: 17030912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of novel mutations associated with independent resistance and cross-resistance to isoniazid and prothionamide in Mycobacterium tuberculosis clinical isolates.
    Islam MM; Tan Y; Hameed HMA; Liu Z; Chhotaray C; Liu Y; Lu Z; Cai X; Tang Y; Gao Y; Surineni G; Li X; Tan S; Guo L; Cai X; Yew WW; Liu J; Zhong N; Zhang T
    Clin Microbiol Infect; 2019 Aug; 25(8):1041.e1-1041.e7. PubMed ID: 30583053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of dfrA and inhA mutations to the detection of isoniazid-resistant Mycobacterium tuberculosis isolates.
    Ho YM; Sun YJ; Wong SY; Lee AS
    Antimicrob Agents Chemother; 2009 Sep; 53(9):4010-2. PubMed ID: 19581462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights on the Mechanism of Action of INH-C
    Vila-Viçosa D; Victor BL; Ramos J; Machado D; Viveiros M; Switala J; Loewen PC; Leitão R; Martins F; Machuqueiro M
    Mol Pharm; 2017 Dec; 14(12):4597-4605. PubMed ID: 29091448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis.
    Unissa AN; Subbian S; Hanna LE; Selvakumar N
    Infect Genet Evol; 2016 Nov; 45():474-492. PubMed ID: 27612406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens.
    Hillemann D; Rüsch-Gerdes S; Richter E
    J Clin Microbiol; 2007 Aug; 45(8):2635-40. PubMed ID: 17537937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlations of mutations in katG, oxyR-ahpC and inhA genes and in vitro susceptibility in Mycobacterium tuberculosis clinical strains segregated by spoligotype families from tuberculosis prevalent countries in South America.
    Dalla Costa ER; Ribeiro MO; Silva MS; Arnold LS; Rostirolla DC; Cafrune PI; Espinoza RC; Palaci M; Telles MA; Ritacco V; Suffys PN; Lopes ML; Campelo CL; Miranda SS; Kremer K; da Silva PE; Fonseca Lde S; Ho JL; Kritski AL; Rossetti ML
    BMC Microbiol; 2009 Feb; 9():39. PubMed ID: 19228426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations of rpoB, katG, inhA and ahp genes in rifampicin and isoniazid-resistant Mycobacterium tuberculosis in Kyrgyz Republic.
    Isakova J; Sovkhozova N; Vinnikov D; Goncharova Z; Talaibekova E; Aldasheva N; Aldashev A
    BMC Microbiol; 2018 Mar; 18(1):22. PubMed ID: 29566660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanism of the synergistic activity of ethambutol and isoniazid against
    Zhu C; Liu Y; Hu L; Yang M; He ZG
    J Biol Chem; 2018 Oct; 293(43):16741-16750. PubMed ID: 30185616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome sequencing of Mycobacterium tuberculosis clinical isolates revealed isoniazid resistance mechanisms undetected by conventional molecular methods.
    Laurent S; Zakham F; Bertelli C; Merz L; Nicod L; Mazza-Stalder J; Greub G; Jaton K; Opota O
    Int J Antimicrob Agents; 2020 Aug; 56(2):106068. PubMed ID: 32603684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in clinical Mycobacterium tuberculosis complex clinical isolates].
    Aslan G; Tezcan S; Emekdaş G
    Mikrobiyol Bul; 2009 Apr; 43(2):217-26. PubMed ID: 19621606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin.
    Safi H; Sayers B; Hazbón MH; Alland D
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2027-34. PubMed ID: 18378710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel loci associated with mycobacterial isoniazid resistance.
    Viswanathan G; Yadav S; Raghunand TR
    Tuberculosis (Edinb); 2016 Jan; 96():21-6. PubMed ID: 26786650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characteristics of rifampin and isoniazid resistant Mycobacterium tuberculosis strains from Beijing, China.
    Jiao WW; Mokrousov I; Sun GZ; Li M; Liu JW; Narvskaya O; Shen AD
    Chin Med J (Engl); 2007 May; 120(9):814-9. PubMed ID: 17531124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of catalase-peroxidase (KatG) mutations in mediating isoniazid resistance in clinical strains of Mycobacterium tuberculosis.
    Unissa AN; Doss C GP; Kumar T; Sukumar S; Lakshmi AR; Hanna LE
    J Glob Antimicrob Resist; 2018 Dec; 15():111-120. PubMed ID: 29990547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.